Status:
COMPLETED
Home Monitoring in Idiopathic Pulmonary Fibrosis; Improving Use of Anti-fibrotic Medication and Quality of Life
Lead Sponsor:
Erasmus Medical Center
Collaborating Sponsors:
OLVG
St. Antonius Hospital
Conditions:
Idiopathic Pulmonary Fibrosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In this study it will be investigate whether a home monitoring program improves disease-specific health-related quality of life (HRQOL) for patients with idiopathic pulmonary fibrosis (IPF) through ap...
Detailed Description
IPF is a chronic disease with progressive scarring of the lung tissue (fibrosis), resulting in a poor prognosis and a devastating impact on the lives of patients and their families. Progressive shortn...
Eligibility Criteria
Inclusion
- All patients with a diagnosis of IPF according to the ATS 2011 criteria and about to start on anti-fibrotic treatment (either nintedanib or pirfenidone)
Exclusion
- Not able to speak, read or write in Dutch
- No access to internet
Key Trial Info
Start Date :
January 9 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 26 2019
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT03420235
Start Date
January 9 2018
End Date
August 26 2019
Last Update
January 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Erasmus MC
Rotterdam, South Holland, Netherlands, 3015 CE